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Introduction
Personalized medicine is a medical model that separates patients into different groups - with med-
ical decisions, practices, interventions and/or products being tailored to the individual patient based on
their predicted response or risk of disease (1). Owing to advances in the field of genetics and genomics,
the medical community is able to gain understanding of various diseases on a molecular level. As a
result, the approach of personalized medicine, an innovative approach that takes into account differences
in people’s genes, environments and lifestyles, is of great interest to doctors and policymakers alike (2).
Numerous governmental agencies, such as National Institutes of Health (NIH) and U.S. Food and Drug
Administration (FDA), are actively engaged in research and regulatory activities associated with person-
alized medicine: The Human Genome Project and thousands of follow-on studies are helping scientists
to develop gene-targeted treatments (2, 3); President Obama launched the Precision Medicine Initiative
in January 2015, which also seeks to identify genetically-based drivers of disease in order to develop new,
more effective treatments (2). However, the concept of personalized medicine is not limited to genetics
and has broadened to encompass various personalization measures, such as differential dosing (4).
Usually, there are large numbers of covariates in datasets associated with personalized medicine.
To develop strategies for performing analysis on these datasets, it is critical to identify the interactions
between treatment and baseline covariates in randomized clinical trials. One commonly used approach
is subgroup analysis, where treatment and control arms are compared in different predefined subgroups,
such as male and female subjects. More rigorously, the treatment-covariates interactions can be analyzed
in a multivariate regression analysis where the product of the treatment variable and a set of baseline
covariates are included in the regression model, as demonstrated by Tian et al. (5).
In this text, the methodology developed by Tian et al. is verified by the author via a number of
numerical simulations: an arbitrary collection of random variables are generated to represent baseline
covariates, and “true” treatment effect for each subject is calculated using a preset formula. By coding
2the treatment variable as ±1 and fitting the products of the treatment variable and baseline covariates
(which essentially are treatment/covariate interaction terms) in a LASSO regression model, a score could
be constructed to select a subgroup of patients who may benefit from a specific treatment. Subsequently,
the method is applied to the collection of random variables to determine treatment scores for all subjects.
Finally, Spearman’s correlation coefficients between treatment scores and treatment effect are calculated
to evaluate the performance of the score. A high Spearman’s correlation coefficient suggests that the
calculated score is a good predictor of “true” treatment effect, and vice versa.
Methods
In this section, we define T = ±1 as the binary treatment indicator. Y (1) and Y (−1) are defined
as the potential outcome for patients who received treatment T = 1 and −1 respectively. We only
observe Y = Y (T ), T and Z, a q-dimensional baseline covariate vector. We assume that treatment is
randomly assigned to a patient, which means that T and Z are independent. Furthermore, we let W be
a p-dimensional function of baseline covariates Z. W(Zi) is denoted as Wi in the rest of this article.
For simplicity, we also assume that P (T = 1) = P (T = −1) = 1/2. Finally, we assume that Y is a
continuous response. We examined two different methods in the article authored by Tian et al.: the full
regression method and the modified covariate method.
Full Regression Method
When Y is a continuous response, a simple multivariate linear regression model could be con-
structed as follows to include interactions between the treatment and the covariates:
Y = β
′
0W(Z) + γ
′
0W(Z) · T/2 +  (1)
where β′0 and γ
′
0 are transposed vectors of coefficients in the linear model and  is the mean zero random
error. According to Tian et al., the interaction term γ′0W(Z) ·T models the differential treatment effect
across the population and the linear combination of γ′0W(Z) can be used for identifying potential sub-
group(s) of patients who may benefit from the treatment. Since the vector W(Z) contains an intercept,
the main effect for treatment is always included in the model. Specifically, under model (1), we have
∆(z) = E(Y (1) − Y (−1)|Z = z) = γ′0W(Z) (2)
that is, ∆(z) = γ′0W(Z) measures the causal treatment effect for patients with the baseline covariate z.
3With observed data, γ0 can be estimated via the ordinary least squares method.
Modified Covariate Method
Alternatively, we consider the following model with only interaction terms:
Y = γ
′
0W(Z) · T/2 +  (3)
where  is random error. That is, we perform a regular linear regression using the product of each
component of Wi and one-half the treatment indicator (T = ±1), without including an intercept. The
detailed steps for carrying out this operation is as follows:
1. Transform the covariate
Zi →Wi = W(Zi)→W∗i = Wi · Ti/2 (4)
2. Fit linear regression
Y ∼ γ′0W∗ (5)
based on modified observations without intercept
(W∗i , Yi) = {(Wi · Ti)/2, Yi}, i = 1, 2, · · · , N. (6)
3. γˆ′W(z) could be used to stratify patients for individualized treatment selection.
(Refer to Tian et al., Journal of American Statistical Association, December 2014, Volume 109,
for more detailed information)
Simulation Studies
In this section, the author performed independent numerical studies with similar data settings to
validate the performance of both methods as demonstrated by Tian et al. with continuous responses.
For each set of simulation, we generated a training dataset and a validation dataset with sample sizes of
N1 = 100 and N2 = 300, respectively. For both datasets, we generated independent Gaussian samples
from the regression model
4Y =
β0 + p∑
j=1
βjZj
2 +
γ0 + p∑
j=1
γjZj + 0.8Z1Z2
T + σ0 · , (7)
where the covariates (Z1, Z2, · · · , Zp) follow a mean zero multivariate normal distribution with a com-
pound symmetric variance-covariance matrix, (1−ρ)Ip+ρ1′1, and  ∼ N(0, 1). We let (γ0, γ1, γ2, γ3, γ4, γ5,
· · · , γp) = (0.4, 0.8,−0.8, 0.8,−0.8, 0, · · · , 0), σ0 =
√
2, N1 = 100, and p = 50 and 1000 representing low
and high-dimensional cases, respectively. The treatment was generated as 1 or −1 with equal probability
(essentially a transformed Bernoulli random variable). We consider 4 different data settings:
1. β0 = (
√
6)−1, β1 = β2 = 0, β3 = β4 = · · · = β10 = (2
√
6)−1, and β11 = · · · = βp = 0. ρ = 0.
2. β0 = (
√
6)−1, β1 = β2 = 0, β3 = β4 = · · · = β10 = (2
√
6)−1, and β11 = · · · = βp = 0. ρ = 1/3.
3. β0 = (
√
3)−1, β1 = β2 = 0, β3 = β4 = · · · = β10 = (2
√
3)−1, and β11 = · · · = βp = 0. ρ = 0.
4. β0 = (
√
3)−1, β1 = β2 = 0, β3 = β4 = · · · = β10 = (2
√
3)−1, and β11 = · · · = βp = 0. ρ = 1/3.
According to Tian et al., settings 1 and 2 represent cases with relatively small main effects, where the
variations in responses contributable to the main effect, interaction, and random error were about 37.5%,
37.5%, and 25%, respectively, when the covariates were correlated. Settings 3 and 4 represent cases with
relatively large main effects, where the variations in responses contributable to the main effect, interac-
tion, and random error were about 75%, 15%, and 10%, respectively, when the covariates were correlated.
For each of the simulated dataset, we applied both the full regression method and the modified
covariate method:
• Full regression: we fitted the model specified in formula (1), with complete main effects and
covariate-treatment interaction terms. LASSO was used to select the variables.
• Modified covariate: we fitted the model specified in formula (3), with the modified covariate
W∗ = (1,Z)′ · T/2. LASSO was also used to select the variables.
For both methods, LASSO penalty parameter was selected by 10-fold cross validation. The
outputs of both methods are estimated scores, γˆ′W(z), where γˆ′ is the estimated coefficients for the
covariate-treatment interaction terms (corresponds to γ’s in formula (1)) in the full regression method
and the estimated coefficients for modified covariates (corresponds to γ’s in formula (3)) in the modified
covariate method. The performance of the resulting score is evaluated by estimating the Spearman’s
rank correlation coefficient between the estimated score and the “true” treatment effect
5∆(z) = E(Y (1) − Y (−1)|Z = z) = 1.6× (0.5 + Z1 − Z2 + Z3 − Z4 + Z1Z2)
in the validation set of size N2 = 300 generated above. Based on 500 sets of simulations for the low-
dimensional case and 200 sets of simulations for the high-dimensional case, we plotted the boxplots of the
rank correlation coefficients between the estimated scores γˆ′W(Z) and ∆(Z) under all 4 data settings,
and compared the boxplots to the boxplots in the Tian et al. article to complete the validation process
of their methods.
Results
The boxplots of Spearman’s rank correlation coefficients for both methods are as follows. Figures 1,
2, 3 and 4 represents data settings 1, 2, 3 and 4, respectively. Empty boxplots indicate high-dimensional
(p = 1000) covariates, whereas filled boxplots indicate low-dimensional (p = 50) covariates.
Figure 1: Moderate main effect, independent covariates. Empty and filled boxplots indicate high- and
low- dimensional cases respectively.
6Figure 2: Moderate main effect, correlated covariates. Empty and filled boxplots indicate high- and low-
dimensional cases respectively.
Figure 3: Big main effect, independent covariates. Empty and filled boxplots indicate high- and low-
dimensional cases respectively.
7Figure 4: Big main effect, correlated covariates. Empty and filled boxplots indicate high- and low-
dimensional cases respectively.
Discussion
In the results section, the author examined both methods in Tian et al.’s article, the full regression
method and modified covariates method, for estimating treatment effect based on a number of baseline
covariates by replicating the numerical studies that they have performed.
For the full regression method, treatments are coded as T = ±1 and all baseline covariates and
covariate/treatment interaction terms are included in a regular linear model. The article by Tian et al.
demonstrated that this method is inferior to the modified covariates method by showing that Spearman’s
correlation coefficients between estimated scores and “true” treatment effect under this method are lower
than that of modified covariates method. However, using independently generated data, the author was
not able to replicate Tian et al.’s results for the full regression method despite careful imitation of their
data settings; in fact, the opposite result was achieved (see Figures 1-4). It is clear that additional
investigation will be required to fully understand the reason of this contradiction.
For the modified covariates method, the general idea is to use W(Z) · T/2 as new covariates in
a regression model to predict the outcome. This provides an efficient approach for constructing a score
to estimate the individualized treatment effect as a function of given covariates. Using independently
8generated data, the author was able to generate boxplots that are highly similar to those produced by
Tian et al for the modified covariates method. Thus, this method is likely to be valid, and it provides
a casual but theoretically sound tool to assign different treatments in clinical trials with a personalized
medicine approach. However, the superiority of this method could not be replicated.
As a limitation, this method is primarily designed for analyzing data from randomized clinical
trials. When applied to an observational study, where the covariates and treatment assignment are likely
not independent, the constructed score might not apply. According to the boxplots, it is also evident that
the performance of the method, especially when applying to correlated high-dimensional data, is limited.
Furthermore, although the modified covariates method aims to estimate the individualized treatment
effect with casual interpretation, the method is not immune to common problems encountered in high-
dimensional data analysis such as multiple testing and over-fitting according to Tian et al. Therefore,
the method is just an exploratory tool, and it is important to withhold a validation set for verification
of the estimated interactions.
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